Guardant Health, Inc. $GH Shares Bought by Aquatic Capital Management LLC

Aquatic Capital Management LLC increased its position in Guardant Health, Inc. (NASDAQ:GH) by 17.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 183,576 shares of the company’s stock after acquiring an additional 27,612 shares during the period. Aquatic Capital Management LLC owned approximately 0.15% of Guardant Health worth $11,470,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Sound Income Strategies LLC bought a new position in Guardant Health in the 3rd quarter worth about $38,000. Allworth Financial LP boosted its position in shares of Guardant Health by 358.4% during the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after buying an additional 552 shares during the period. Optiver Holding B.V. boosted its position in shares of Guardant Health by 153.5% during the third quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock worth $48,000 after buying an additional 465 shares during the period. Smartleaf Asset Management LLC grew its holdings in Guardant Health by 162.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,096 shares of the company’s stock worth $68,000 after buying an additional 678 shares in the last quarter. Finally, Bayforest Capital Ltd bought a new position in Guardant Health in the 3rd quarter worth approximately $78,000. 92.60% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $91.54, for a total value of $119,002.00. Following the transaction, the director directly owned 1,193 shares of the company’s stock, valued at $109,207.22. This trade represents a 52.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Terilyn J. Monroe sold 8,571 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $114.09, for a total transaction of $977,865.39. Following the sale, the insider owned 20,990 shares in the company, valued at $2,394,749.10. This represents a 28.99% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 20,018 shares of company stock worth $2,232,911. Corporate insiders own 6.10% of the company’s stock.

Guardant Health Stock Up 1.7%

Shares of NASDAQ GH opened at $85.49 on Monday. The stock’s fifty day simple moving average is $103.92 and its 200 day simple moving average is $90.02. The stock has a market capitalization of $11.21 billion, a price-to-earnings ratio of -25.83 and a beta of 1.67. Guardant Health, Inc. has a 52-week low of $36.36 and a 52-week high of $120.74.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same period last year, the company posted ($0.62) earnings per share. The firm’s revenue was up 39.4% compared to the same quarter last year. As a group, analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on GH. Mizuho set a $135.00 target price on Guardant Health in a research report on Friday, January 9th. Guggenheim increased their price target on Guardant Health from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. BTIG Research raised their price target on Guardant Health from $140.00 to $145.00 and gave the company a “buy” rating in a report on Friday, February 20th. Morgan Stanley lifted their price objective on shares of Guardant Health from $105.00 to $130.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Finally, Leerink Partners upped their price objective on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, February 20th. Twenty-one investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $122.57.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.